SCHEMBL1931533

SCHEMBL1931533

CNC(=O)c1ccn2c(C(=O)c3ccc(N)c(OC)c3)nc(-c3cccc(C(=O)O)c3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AVPR2 P30518 1/20 0.39
▸ AVPR1A P37288 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ KDM5A P29375 1/20 0.38
▸ KDM4C Q9H3R0 1/20 0.38
▸ KDM5B Q9UGL1 1/20 0.38
▸ FYN P06241 1/20 0.38
▸ LRRK2 Q5S007 1/20 0.38
▸ SYK P43405 4/20 0.37
▸ AKT1 P31749 1/20 0.37
▸ AKT2 P31751 1/20 0.37
▸ RORC P51449 1/20 0.36
▸ PDE4D Q08499 1/20 0.35
▸ KARS1 Q15046 1/20 0.35
▸ MAP3K14 Q99558 1/20 0.35
▸ CREBBP Q92793 1/20 0.35
▸ MAP4K4 O95819 1/20 0.35
▸ CSNK2A1 P68400 1/20 0.35
▸ MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4509705 0.91 PDE4D (0.38) KDM4CKDM5BSYKAKT1AKT2
SCHEMBL1931163 0.88 CSNK2A2 (0.44) RORCMAP3K14MEN1NPC1KMT2A
SCHEMBL1932541 0.86 RORC (0.50) RORC
SCHEMBL13918692 0.81 GAA (0.39) FYNPDE4DKMT2AROCK2ROCK1
SCHEMBL1931204 0.80 RORC (0.43) KDM5BAKT1AKT2RORCPDE4D
SCHEMBL1573248 0.79 TNK2 (0.38) SYKRORCPDE4DMEN1NPC1
SCHEMBL4502430 0.77 NR1H4 (0.42) KMT2A
SCHEMBL1932592 0.76 MAPT (0.45) RORCMAP3K14NPC1RAB9ASMN1; SMN2
SCHEMBL1933051 0.75 RORC (0.43) RORCMAP3K14
SCHEMBL1573291 0.75 TNK2 (0.37) SYKRORCPDE4DLDHA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633216-B2 Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI (FR) 2014-01-21 — — US disclosed
US-8008321-B2 Imidazo[1,5-a]pyridin-3-yl)(3-methoxy-4-nitrophenyl)methanone; a and b fibroblast growth factor receptors (FGFR) antagonist; anticarcinogenic, antitumor: lung, breast, prostate, melanomas, gliomas; antiinflammatory, vascular smooth muscle cells: atherosclerosis, restenosis, stent and bypass complications SANOFI-AVENTIS (FR) 2011-08-30 — — US disclosed
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2011-06-09 — — US disclosed
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-05-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108648-A1 Novel imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same CYP3A5, CYP4B1, CYP3A7 AVPR2 625/4885AVPR1A 685/4885JAK2 357/4885
US-20110136856-A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same P2RX6, IL5, ATIC AVPR2 527/4885AVPR1A 721/4885JAK2 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback